Ishita Drugs and Industries Limited

ISHITADR6

INE806D01016

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:57 28/06/2024 pm IST			5-day change	1st Jan Change
66.76 ^INR	+1.54%		+1.83%	-7.20%

30/05	Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
13/02	Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Ishita Drugs & Industries Limited Approves Resignation of Shyamkumar Agrawal from the Position of Independent Director

November 12, 2019 at 08:03 pm IST

Ishita Drugs & Industries Limited at its board meeting held on November 12, 2019 approved resignation of Dr. Shyamkumar Agrawal with effect from closing business hours of November 12, 2019 and also placed on record their appreciation for the valuable contribution made by him during his tenure as an Independent Director of the company.

Latest news about Ishita Drugs and Industries Limited

Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	30/05	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	12/23/12	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	30/23/30	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	14/23/14	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/22/13	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	02/21/02	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the First quarter Ended June 30, 2021	13/21/13	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/21/30	CI
Ishita Drugs and Industries Limited Announces Appointment of Srushti Pandya as Company Secretary and Compliance Officer, Effective February 4, 2021	04/21/04	CI
Ishita Drugs and Industries Limited Announces Resignation of Vijay Shah from the Post of Company Secretary and Compliance Officer	04/21/04	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	04/21/04	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	09/20/09	CI
Ishita Drugs & Industries Limited Appoints Vijay Shah as Company Secretary and Compliance Officer	31/20/31	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	13/20/13	CI
Ishita Drugs & Industries Limited Accepts Resignation of Prakash Ranjan Rastogi from the Position of Independent Non-Executive Director	30/20/30	CI
Ishita Drugs & Industries Limited Announces Resignation of Niharika Shah as Company Secretary and Compliance Officer	30/20/30	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	30/20/30	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	11/20/11	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	12/19/12	CI
Ishita Drugs & Industries Limited Approves Resignation of Shyamkumar Agrawal from the Position of Independent Director	12/19/12	CI
Ishita Drugs and Industries Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2019	13/19/13	CI

Chart Ishita Drugs and Industries Limited

Duration

Period

Chart Ishita Drugs and Industries Limited

More charts

Company Profile

Ishita Drugs and Industries Limited is a manufacturer of various active pharma ingredients (APIs) (bulk actives and their salts), drug intermediates, excipients, and fine chemicals. The Company's APIs include sulpha drugs/sulfonamides, vitamins, fluoroquinolones, antibiotics, anthelmintics, iodides and citrates (salts), food additive/excipients, and others. Its drug intermediates include 4- Sulfonamido Phenyl Hydrazine Hydrochloride (Celecoxib Intermediate), 4- Chloro Phenyl Hydrazine Hydrochloride (intermediate for Indole Carboxylic Acid), L-Alanine Benzylester Tosylate, 5 Cyano Phthalide (Citalopram Intermediate), Indole 2 Carboxylic Acid, Ethyl 3-Benzoyl Acrylate, Hexa Methyl Disilazane, 5-Chloromethopabate, and others. Its fine chemicals include salicylanilide, para bromo toluene, pyridine hydrobromide, potassium phthalimide, nicotinic acid hydrazide, 3 amino pyridine, methyl iodide. The Company has three manufacturing facilities located in the state of Gujarat.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ISHITA DRUGS AND INDUSTRIES LIMITED	-7.20%	23.95L
ELI LILLY AND COMPANY	+55.32%	82TCr
NOVO NORDISK A/S	+44.05%	64TCr
JOHNSON & JOHNSON	-6.75%	35TCr
MERCK & CO., INC.	+13.56%	31TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr
PFIZER, INC.	-2.81%	16TCr